Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in TaiwanChi‐Yi Chen, Ming‐Lung Yu, Yi‐Hsiang Huang et al.|Liver International|2021Cited by 57
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen‐Hua Liu, Jia‐Horng Kao, Chi-Yi Chen et al.|Gut|2021Cited by 39
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)Chung‐Feng Huang, Ming‐Lung Yu, Kuo‐Chih Tseng et al.|Clinical Gastroenterology and Hepatology|2021Cited by 32
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in TaiwanPin‐Nan Cheng, Lein‐Ray Mo, Chun‐Ting Chen et al.|Infectious Diseases and Therapy|2021Cited by 28
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis‐related complications (Taiwanese chronic hepatitis C cohort)Wei‐Fan Hsu, Cheng‐Yuan Peng, Pei‐Chien Tsai et al.|Journal of Gastroenterology and Hepatology|2021Cited by 23